What SEC filings does MaxCyte, Inc. submit to the SEC?

MaxCyte, Inc. (MXCT) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about MXCT?

A Form 4 for MXCT discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from MaxCyte, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for MXCT?

The 10-K is MaxCyte, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all MXCT SEC filings directly on EDGAR?

You can view all historical MaxCyte, Inc. filings on the SEC EDGAR company page for MXCT. Each filing card on this page links directly to the original SEC document.

How often does MaxCyte, Inc. file with the SEC?

MaxCyte, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling MXCT shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

MXCT SEC Filing News — MaxCyte, Inc.

Latest SEC filings for MaxCyte, Inc. (MXCT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-14.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applicatio…

Sector: Healthcare Industry: Medical Devices Market Cap: $147.6M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

What you're looking at: Each item below is parsed from an actual SEC filing submitted by MaxCyte, Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.

MXCT Filing Activity Snapshot 2026-03-25 — 2026-10-14

Insider Transactions (Form 4)

0 buys vs 0 sells

Insider buying and selling activity is balanced in this period.

Insider Transactions 11 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 11 filings in this group are Form 4s for MaxCyte, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 11 insider filings shown, the breakdown is 11 compensation award. None of the classified filings involved a discretionary open-market trade, so this period says nothing about what insiders think of the price.

What each transaction type means

Compensation award ×11: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

Johnston John Joseph (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	30,421	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	49,579	—	—

Filing: Form 4 (Insider Transaction) Insider: Johnston John Joseph (Director) Shares: 30,421

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

Hemrajani Rekha (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	30,421	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	49,579	—	—

Filing: Form 4 (Insider Transaction) Insider: Hemrajani Rekha (Director) Shares: 30,421

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

Erck Stanley C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	30,421	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	49,579	—	—

Filing: Form 4 (Insider Transaction) Insider: Erck Stanley C (Director) Shares: 30,421

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

DOUGLAS RICHARD (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	30,421	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	49,579	—	—

Filing: Form 4 (Insider Transaction) Insider: DOUGLAS RICHARD (Director) Shares: 30,421

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

Collins Cynthia (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	30,421	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	49,579	—	—

Filing: Form 4 (Insider Transaction) Insider: Collins Cynthia (Director) Shares: 30,421

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

Brooke William W (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	30,421	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	49,579	—	—

Filing: Form 4 (Insider Transaction) Insider: Brooke William W (Director) Shares: 30,421

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

BALTHROP PATRICK J (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	30,421	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	49,579	—	—

Filing: Form 4 (Insider Transaction) Insider: BALTHROP PATRICK J (Director) Shares: 30,421

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-22

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

Al-Wakeel Yasir B. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	30,421	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	49,579	—	—

Filing: Form 4 (Insider Transaction) Insider: Al-Wakeel Yasir B. (Director) Shares: 30,421

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-17

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

Ahuja Parmeet (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	187,500	—	—

Filing: Form 4 (Insider Transaction) Insider: Ahuja Parmeet (Chief Financial Officer) Shares: 187,500

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-04-10

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (right to buy)	375,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Ahuja Parmeet (Chief Financial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-03-31

MXCT insider Form 4 filed for equity award, exercise, or tax withholding

Masoud Maher (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	300,000	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	600,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Masoud Maher (Director, President and CEO) Shares: 300,000

View on SEC EDGAR → Open Filing Document →

Material Events 6 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 6 in this period for MaxCyte, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-14

MXCT filed 8-K — material company event

MAXCYTE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-12

MXCT filed 8-K — material company event

MAXCYTE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-17

MXCT filed 8-K — material company event

MAXCYTE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-16

MXCT filed 8-K — material company event

MAXCYTE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-05-12

MXCT filed 8-K — material company event

MAXCYTE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-03-27

MXCT filed 8-K — material company event

MAXCYTE, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 3 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 annual report (10-K) and 2 quarterly reports (10-Q) for MaxCyte, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-13

MXCT filed Quarterly Report (10-Q)

MAXCYTE, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-Q Quarterly Report 2026-05-13

MXCT filed Quarterly Report (10-Q)

MAXCYTE, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

Form 10-K Annual Report 2026-03-25

MXCT filed Annual Report (10-K)

MAXCYTE, INC. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.

Filing: 10-K (Annual Report)

View on SEC EDGAR → Open Filing Document →

How we classify MaxCyte, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on MXCT. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — MXCT SEC Filings

More Tools for MXCT

MXCT Full Stock Analysis MXCT Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper MXCT analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the MXCT stock analysis page.

MXCT Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer